Exectuive Moves: GlaxoSmithKline

Andrew Witty has been appointed chief executive officer designate, GlaxoSmithKline. Mr. Witty, currently president, Pharmaceuticals Europe for GSK, will succeed Dr. Jean-Pierre Garnier following his retirement as chief executive officer at the end of May 2008.

Sir Christopher Gent, chairman, GlaxoSmithKline said, “Andrew’s appointment follows a rigorous selection process by the board of directors. The fact that we have been able to select a successor to JP from three strong internal candidates is a testament to the quality of management at GSK. The Board is confident that Andrew will build on JP’s considerable achievements which have positioned GSK as a leader of the pharmaceutical industry.”

Dr. Garnier said, “Andrew has made many significant contributions to GSK and I am very pleased that he is to be our next CEO. I look forward to working with him during our handover and wish him every success.”